BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

Original reporting
Published Nov 20, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BCLI
Neutral
medium confidence
Mentioned
$BCLI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BCLINeutralMed
01

Why it matters

If the court approves, current stockholders are barred from contesting the settlement and pursuing released claims, and the company will benefit from specified corporate governance reforms. However, the notice summarizes allegations involving FDA invalidation of a hypothesis, manufacturing deficiencies, and safety concerns in the NurOwn Phase 3 trial.

02

Market read

This is a litigation-resolution catalyst that can reduce overhang, but it also keeps prominent the FDA and disclosure-related allegations that may continue to influence valuation.

03

What to watch

Court approval timing, potential fee/service award scrutiny, and whether the governance reforms are substantive enough to change future FDA interaction and reporting practices.

Relevance 7/10Novelty 6/10Timing: Ahead of the court fairness hearing on the proposed settlement.

Background

The 8-K Item 7.01 furnishes a notice of pendency and proposed settlement for Brainstorm Cell Therapeutics stockholder derivative matters, alongside a related Delaware Section 220 books-and-records action.

Company-level read

Ticker impact

$BCLINeutralMedium confidence
Context

Brainstorm Cell Therapeutics filed an 8-K describing a proposed settlement and dismissal with prejudice of its stockholder derivative litigation, including FDA-related allegations.

Expected impact

Likely modest relief bid on settlement approval odds, with continued headline risk if investors focus on the alleged FDA and disclosure issues.

Evidence & confidence

The filing is a court notice of pendency and proposed settlement, not a merits ruling. It signals progress toward resolution and governance reforms, but it also reiterates serious alleged misconduct tied to FDA communications and trial safety concerns.

Market effects

For biotech, derivative settlements tied to FDA communications can reinforce investor focus on disclosure quality and trial safety narratives.

Limited, primarily affecting US small-cap biotech sentiment and litigation-risk pricing.

Low, as this is company-specific litigation in US courts.

Counterpoint

Even with a settlement, investors may treat the reiterated FDA and misstatement allegations as a negative signal about historical regulatory and clinical risk, limiting any relief rally.

Key entities

  • Brainstorm Cell Therapeutics Inc.

    Nominal defendant in the derivative action and subject of the proposed settlement notice.

  • United States District Court for the Southern District of New York

    Will hold a hearing to consider fairness, reasonableness, and adequacy of the proposed settlement.

  • Delaware Court of Chancery

    Has a pending Section 220 inspection action related to books and records.

Related articles

$BCLIMed

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

$FMed

Ford launches Super Dutys at Oakville, a boon for tariff-hit Canada

Ford Motor Co. has resumed F-Series Super Duty truck production at its Oakville Assembly Complex in Canada, following a $3.5 billion investment. The move aims to meet demand, reduce wait times, and support Canada's automotive industry amid tariffs and plant closures by competitors. The Canadian government and Ontario province contributed $324 million and $206 million, respectively.

$BAYN.DEHighAI 8/10

Bayer’s $7.25 Billion Roundup Settlement Approved by US Judge

A Missouri judge approved Bayer AG's $7.25 billion settlement to resolve U.S. lawsuits linking Roundup weedkiller to cancer. The German company inherited the legal issues from its 2018 acquisition of Monsanto, which caused its stock to drop about 80% before recent legal wins. The case is Randall King v. Monsanto, Missouri Circuit Court Twenty-Second Judicial District (St. Louis).